NCT00829569 is a NA clinical trial of Intralipid +/- Omegaven in Type 2 Diabetes, sponsored by St. Olavs Hospital.

Who is sponsoring NCT00829569?

NCT00829569 is sponsored by St. Olavs Hospital.

What drugs are being tested in NCT00829569?

Interventions in NCT00829569: Intralipid +/- Omegaven.

What condition does NCT00829569 study?

NCT00829569 studies Type 2 Diabetes.

Is NCT00829569 still recruiting?

NCT00829569 is currently completed. Last updated 3 November 2011.

Last reviewed 2011-11-03 · How we verify

NCT00829569

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Marine n-3 Fatty Acid Infusion on Insulin Sensitivity and Insulin Secretion in Type 2 Diabetes

Completed NA Last updated 3 November 2011

What this trial tests

NA trial testing Intralipid +/- Omegaven in Type 2 Diabetes in 11 participants. Completed in 1 October 2008.

Timeline

1 January 2004

Primary endpoint
1 May 2004

1 October 2008

Quick facts

Lead sponsor	St. Olavs Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	11
Start date	1 January 2004
Primary completion	1 May 2004
Estimated completion	1 October 2008
Sites	1 location across Norway

Drugs / interventions tested

Intralipid +/- Omegaven

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

St. Olavs Hospital

Who can join

Adults 30 to 75, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

insulin sensitivity
Time frame: 4 hours

Sponsor's own description

The purpose of this experimental study is to investigate whether an acute lipid infusion added marine n-3 fatty acids produces effects on insulin sensitivity in subjects with type 2 diabetes, when compared with an acute lipid infusion without marine n-3 fatty acids. Furthermore other effects on intermediary metabolism are tested for.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exploring the Interplay of Antioxidants, Inflammation, and Oxidative Stress: Mechanisms, Therapeutic Potential, and Clinical Implications.
Altanam SY, Darwish N, Bakillah A. · · 2025 · cited 4× · PMID 41002745 · DOI 10.3390/diseases13090309

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other St. Olavs Hospital trials

Trials by the same sponsor.

NCT07331766 — Collaboratory Treatment Pathway for Chronic Pain Patients. · NA · enrolling by invitation
NCT07305025 — Pelvic Pain Electro-Acupuncture · NA · not yet recruiting
NCT07245264 — Adjuvant Tranexamic Acid (TXA) Versus Surgery Alone for Adult Patients With Chronic Subdural Hematoma (CSDH) · Phase 2, PHASE3 · recruiting
NCT07180433 — Piloting 18F-FAPI PET/MRI for Applications in Breast Cancer · NA · not yet recruiting
NCT06854861 — Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes · Phase 1, PHASE2 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00829569 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Olavs Hospital
Last refreshed: 3 November 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00829569.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing